Objectives: Although access to antiretroviral therapy is being improved in the resource-limited settings most affected by the HIV pandemic, the assessment of treatment success or failure remains a challenge. Methods of viral load determination that are inexpensive, easy to use, and practicable at peripheral health centers are required. This study aimed at evaluating the validity and relative cost of a manual method compared to an automated method of viral load quantification.
Methods: HIV-1 viral load was determined by both the COBAS Amplicor HIV-1 Monitor and the Amplicor HIV-1 Monitor assays in 18 patients in Yaounde, Cameroon.
Results: There was a strong correlation between values of viral load obtained by the automated method and the manual method (r = .83, P value < .0001). Also, both methods were not statistically different from each other (Wilcoxon rank-sum statistic P value .99).
Conclusions: The manual method of determining HIV viral load was correlated with the automated method and should be considered as a viable alternative.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1545109711398663 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Examining teen club attendance and viral load suppression among adolescents under differentiated HIV care in Malawi: a sub-optimal scenario.
BMC Public Health
December 2024
Research Department, Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), Lilongwe, Malawi.
Background: In Malawi, compared to adults, adolescents have higher rates of high HIV viremia and poorer antiretroviral therapy (ART) outcomes. The Ministry of Health, supported by the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF), implemented the provision of differentiated care clubs for adolescents living with HIV (ALHIV), called "teen clubs," to provide psychosocial support and an HIV care package to improve clinical outcomes. We evaluated teen club attendance and factors associated with unsuppressed viral load (VL) in ALHIV enrolled in these teen clubs.
View Article and Find Full Text PDFHIV-1 Viremia and Cancer Risk in 2.8 Million People: the South African HIV Cancer Match Study.
Clin Infect Dis
December 2024
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Background: Most research on HIV-1 viremia and cancer risk is from high-income countries. We evaluated the association between HIV-1 viremia and the risk of various cancer types among people with HIV (PWH) in South Africa.
Methods: We analysed data from the South African HIV Cancer Match study, based on laboratory measurements from the National Health Laboratory Services and cancer records from the National Cancer Registry from 2004-2014.
Ocular and Adnexal Diseases in Human Immunodeficiency Virus-Infected Pregnant Women Attending HIV Clinics in Ibadan, Nigeria.
J West Afr Coll Surg
October 2024
Adeoyo Maternity Teaching Hospital, Ibadan, Nigeria.
Background: Human immunodeficiency virus (HIV) is a lentivirus. It is transmitted through sexual intercourse, shared intravenous drugs, contaminated needle use, blood transfusion, and mother-to-child transmission. Of the patients with HIV, 50%-75% have ocular manifestations and this may be the primary presentation.
View Article and Find Full Text PDFMultiorgan and Multisystem Involvement During Primary HIV Infection: A Case Report With a Literature Review.
Cureus
November 2024
Urology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND.
The initial six months following HIV infection have a high viral load. Nonspecific presentations might lead to the missing primary HIV diagnosis. Multiorgan and multisystem diagnosis is a rare presentation of primary HIV.
View Article and Find Full Text PDFAcute Hepatitis B Infection in a Patient With Confirmed Immunity on Long-Acting Cabotegravir/Rilpivirine.
ACG Case Rep J
January 2025
Internal Medicine, Marshall University Medical Center, Huntington, WV.
Long-acting injectable formulation of cabotegravir/rilpivirine (CAB/RPV) is a promising novel maintenance therapy for HIV infection. However, coinfection with active hepatitis B virus (HBV) infection is a contraindication to initiating this therapy. Despite guidelines, patients with HBV immunity can still contract acute HBV infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!